In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to ACNAP Silver Members, Fellows of the ESC and Young combined Members

A single centred cross-sectional study of coronary reperfusion times in primary percutaneous coronary intervention (PPCI): an Irish perspective

Session Oral abstract session: PPCI , risk factors and prevention

Speaker Amanda Roe

Congress : EuroHeartCare 2018

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Acute Coronary Syndromes - Treatment
  • Session type : Abstract Session
  • FP Number : 245

Authors : A Roe (Dublin,IE), M Mooney (Dublin,IE)

Authors:
A Roe1 , M Mooney2 , 1St James Hospital - Dublin - Ireland , 2Trinity College Dublin - Dublin - Ireland ,

Citation:
European Journal of Cardiovascular Nursing ( 2017 ) 17 ( Supplement ), S71

Background: The management of ST-elevation myocardial infarction (STEMI) in Ireland changed with the introduction of the National Acute Coronary Syndrome (ACS) model of care in 2012. The model heralded the implementation of a national Primary Percutaneous Coronary Intervention (PPCI) Programme to minimise time to treatment using PPCI in STEMI patients. The programme mandates reperfusion to treat STEMI using PPCI within 120-minutes from first 12 lead ECG diagnosis. Irish data on times to PPCI is limited.
Purpose: The study established cross-sectional data of PPCI patients in an Irish PPCI centre. Objectives included;
1. Ascertain reperfusion time (RT) in all PPCI during the study period.
2. Identify whether patients achieved RT in<120-minutes.
3. Examine factors associated with RT.
Methods: The study was a non-experimental, cross-sectional descriptive design. To be included, patients were diagnosed with STEMI, based on the European Society of Cardiology (ESC 2012) criteria and admitted for emergency PPCI during the 3-month data collection period. Descriptive and inferential statistics were used. The study was ethically approved.
Results: There were 133 patients that met the inclusion criteria initially. Of these, 105 (79%) received PPCI, while the remaining 28 had differential diagnosis, based on their angiogram. The sample was 74% (N=99) male and the mean age was 62 +/− 11.97 years. 67% of PPCI patients achieved RT within 120-minutes from 12 lead ECG diagnosis, with a median RT of 96 minutes. The majority of STEMIs (46%) were diagnosed by paramedics. In this study, there was a significant difference (p=0.006) in the mean age of patients with a RT of <120 minutes (Mean: 59.6, SD: 11.1) and the mean age of those with a RT >120 minutes (Mean: 66.5, SD:13.26), suggesting that younger patients achieve RT in <120 minutes. Source of referral was also significant (p=0.001), in that patients (n=44, 81%) who were transferred directly to the Coronary catheterisation laboratory and bypassed Emergency Departments and non PPCI centres achieved reperfusion within the recommended 120 minutes.
Conclusion: The results suggest that a timely service to STEMI patients is being provided. However 33% fall outside the recommended RT timeframe of 120 minutes. There is scope to further improve these times. The results reported that both age and source of referral were found to be associating factors in achieving reperfusion times within 120 minutes. This study recommends a multi-centre study to represent the greater Irish STEMI population.

The free consultation period for this content is over.

It is now only available year-round to ACNAP Silver Members, Fellows of the ESC and Young combined Members



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are